Phosphate ion (Pi) (Pi)

Phosphate ions in the gastrointestinal tract are the primary therapeutic target for managing hyperphosphatemia in patients with advanced chronic kidney disease (CKD). In healthy individuals, dietary phosphate is absorbed in the small intestine and regulated by the kidneys to maintain mineral homeostasis (StatPearls, 2023) [1]. However, renal failure leads to impaired phosphate excretion, resulting in elevated serum levels that trigger secondary hyperparathyroidism and promote vascular calcification (KDIGO, 2017) [3]. Phosphate binders, including calcium-based and non-calcium-based agents, are administered to interact directly with these ions within the gut lumen (American Family Physician, 2014) [5]. These drugs function by forming insoluble complexes with phosphate, thereby preventing its absorption into the systemic circulation and facilitating its excretion in the feces (PubChem) [2]. Effective sequestration of intestinal phosphate is crucial for reducing the risk of cardiovascular events and maintaining bone health in the CKD population (Journal of the American Society of Nephrology, 2010) [4]. This therapeutic approach remains a cornerstone of management for mineral and bone disorders associated with end-stage renal disease.

Other names

Inorganic phosphateOrthophosphatePO4(3-)Dietary phosphatePhosphate ions in the gastrointestinal tract

Phosphate binders act by sequestering dietary phosphate ions in the gastrointestinal tract through chemical precipitation or physical binding, forming insoluble complexes that are excreted in the feces, thereby reducing systemic absorption (StatPearls, 2023) [1].